Interview with Israel Garcia Crespo, General Manager, Almirall Mexico
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Address: Periferico Sur 3325 Piso 1, Col. San Jeronimo Lidice, Mexico D.F.
,Mexico
Tel: +52 5 559 998 600
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company with headquarters in Spain, based on innovation and committed to health, and develops, manufactures and commercializes its own Research & Development driven licensed drugs, with the aim of improving health and welfare of people. Currently, our drugs are marketed in over 70 countries including the USA and Japan, either through our own subsidiaries or through marketing agreements with renowned pharmaceutical companies. Almirall has 11 subsidiaries in Europe, including Spain, Germany, Austria, Belgium, France, Italy, Poland, Portugal, United Kingdom, Ireland and Switzerland and Mexico. Almirall S.A. de C.V.- the company’s only Latin American presence- began operating in 2000 with the aim of consolidating the company’s international expansion and entering placing its main strategic products into the Mexican market specifically.
Almirall S.A. de C.V. currently has 9 innovative products in the Mexican market in fields ranging from Dermatology to Oncology, which provide solutions to Mexican society in improving their quality of life and health.
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
Gisela Ayala outlines the Mexican Diabetes Federation’s focus on educating people with diabetes, healthcare providers, and the general public to dispel myths and improve diabetes management. She highlights the significant…
Present in Mexico for over 50 years, the medical device firm Medtronic boasts a large manufacturing footprint in the country. VP for North and Latin America and president of the…
Joao Carapeto outlines Roche Diagnostics’ commitment to innovation, prevention, and diagnostics, emphasizing the need for robust partnerships and increased investment in early detection to address Mexico’s healthcare challenges. He highlights…
FUNSALUD is a leading Mexican think tank focused on improving public health through research, advocacy, and promoting public-private partnerships. As Mexico prepares to welcome a new president, FUNSALUD’s Hector Valle…
This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In…
Drawing on an industry track record of over 25 years, Fernando Fogarin has recently become the strategic project lead for emerging markets at women’s health specialist Organon. He shares his…
Mexico’s president-elect Claudia Sheinbaum recently revealed some of her key cabinet choices, naming eminent physician and researcher David Kershenobich as the country’s new health secretary. When Kershenobich takes office in…
The Mexican Diabetes Association (AMD) is an organization dedicated to providing education and training to Mexicans living with diabetes and their families. President Gabriela Allard comments on the importance of…
As the country’s most important patient organization for cancer, the Mexican Association for the Fight Against Cancer (AMLCC) focuses on education, prevention and patient support, as well as on influencing…
Federico Prince, general manager and CEO of Laboratorios Kener details the family-run branded generics company’s changing of hands and the rocky patches it went through before becoming the second-largest company…
Guy Jean Savoir, CEO of family-run Mexican pharma Carnot Laboratories explains the company’s USD 150 million investment in a new facility, its plans to focus manufacturing efforts on vaccines and…
Ana Riquelme Francistain, executive director of the MedTech trade group Asociación Mexicana de Industrias Innovadoras de Dispositivos Médicos (AMID), details the trade and tax incentives that have favoured nearshoring from…
See our Cookie Privacy Policy Here
